Related Experiment Video
Updated: Jul 11, 2026
Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses
Published on: November 3, 2014
Anti-Toxoplasma gondii studies of the venom peptide XYP4 from the Lycosa coelestis
Dongqian Yang1, Xiaohua Liu2, Jing Li2
1Department of Parasitology, Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, PR China; Department of Laboratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, 415003, Hunan, PR China.
Abstract:
Toxoplasma gondii (T. gondii) is an intracellular parasite with multiple routes of infection that poses a serious health risk to pregnant women, fetuses, and immunocompromised populations. Currently, clinical drugs in the treatment of toxoplasmosis continue to face challenges such as drug resistance. In the face of this challenge, researchers have gradually focused on the potential medicinal value of animal venoms in the fight against T. gondii, especially venom peptides showing advantages such as high potency, membrane targeting, and immunomodulation. The present study aimed to explore whether XYP4, a peptide derived from the venom of the Lycosa coelestis (L. coelestis), possesses better anti-T. gondii activity and its mode of action. The experimental results showed that XYP4 is an amphiphilic cationic linear polypeptide with an α-helix, which can exert anti-toxoplasma activity at low concentrations, affecting the lytic cycle. This polypeptide showed moderate survival benefits in mice infected with T. gondii. The main modes of action of XYP4 include inhibition of tachyzoites' intracellular proliferation, modulation of inflammatory factor expression in the host cells, and disruption of tachyzoite membrane integrity.
Insights
Researchers explored XYP4, a peptide from Lycosa coelestis venom, for treating toxoplasmosis. XYP4 peptide effectively combats Toxoplasma gondii by inhibiting parasite growth and disrupting its membrane, offering potential new therapeutic strategies.
Area of Science:
- Parasitology
- Pharmacology
- Biochemistry
Background:
- Toxoplasma gondii (T. gondii) infection, or toxoplasmosis, poses significant health risks, particularly to vulnerable populations.
- Existing treatments for toxoplasmosis face challenges, including increasing drug resistance.
- Animal venoms, specifically venom peptides, are emerging as promising candidates for novel anti-parasitic therapies due to their potency and targeting capabilities.
Purpose of the Study:
- To investigate the anti-T. gondii activity of XYP4, a peptide isolated from Lycosa coelestis (L. coelestis) venom.
- To elucidate the mechanism of action of XYP4 against T. gondii tachyzoites.
- To evaluate the therapeutic potential of XYP4 in a mouse model of toxoplasmosis.
Main Methods:
- Characterization of XYP4 as an amphiphilic cationic linear polypeptide with an alpha-helix structure.
- In vitro assessment of XYP4's activity against T. gondii tachyzoites, including effects on proliferation and membrane integrity.
- In vivo evaluation of XYP4's efficacy in a murine model of toxoplasmosis, monitoring survival rates.
- Analysis of host inflammatory responses, including the modulation of inflammatory factors.
Main Results:
- XYP4 demonstrated significant anti-T. gondii activity at low concentrations, impacting the parasite's lytic cycle.
- The peptide was found to inhibit intracellular tachyzoite proliferation and disrupt tachyzoite membrane integrity.
- XYP4 modulated the expression of inflammatory factors in host cells.
- Administration of XYP4 resulted in moderate survival benefits in T. gondii-infected mice.
Conclusions:
- XYP4 exhibits potent anti-toxoplasmosis properties through multiple mechanisms, including direct parasite inhibition and host immune modulation.
- The peptide's ability to disrupt tachyzoite membranes and inhibit intracellular proliferation highlights its potential as a novel therapeutic agent.
- XYP4 represents a promising lead compound for the development of new drugs against toxoplasmosis, addressing the challenge of drug resistance.
